This protocol applies to patients with upper urinary tract urothelial carcinoma who present with advanced or metastatic disease — including distant metastases or unresectable lymph node metastases — and who are eligible for enfortumab vedotin plus pembrolizumab as first-line treatment.
Current evidence supports a first-line combination regimen involving enfortumab vedotin together with pembrolizumab for eligible patients in this setting. The complete structured protocol — including full eligibility criteria, regimen details, and sequencing — is available via the link below.